• Twenty-four qualitative interviews were conducted with payer decision makers in the EU-5: 12 key opinion leaders (KOLs), 2 laboratory directors, and 10 academic health economists and HTA advisors.
RESULTS AND DISCUSSION

France
HTA
• National level -HTA is primarily conducted nationally by the HAS (National Authority for Health).
-The CNEDiMTS (National Committee for Medical Devices and Technologies Assessment), within HAS, assesses usefulness, interest, and good use of medical devices and other nondrug health care products.
• Regional level -The ARSs (regional health agencies) may conduct a separate assessment but largely rely on national level assessment.
• Hospital level -The COMEDIMS (Committees for Drugs and Sterile Medical Devices) may conduct separate assessments that fit in the diagnosis-related group (DRG) system.
Reimbursement
• National level -The Health Ministry uses appraisals conducted by CNEDiMTS to determine reimbursement for a medical device or diagnostic. Reimbursement rate is 60%.
-The CEPS (Economic Committee for Health Products) determines the price or the tariff after negotiations with the manufacturer.
-The UNCAM (Union of National Health Insurance Funds) coordinates the three mandatory sickness funds and intervenes in negotiations with medical professionals.
-The UNCAM sets coding and fixes medical procedure tariffs based on CNEDiMTS appraisals.
• Regional level -The ARSs plan hospital and ambulatory budgets according to population needs.
• Hospital level -COMEDIMS makes decisions for medical device listings on the hospital formulary. 
Germany
Market Access for POC Diagnostics: Outpatient Sector
• Reimbursement for a POC diagnostic test must fit in an existing EBM (reimbursement tariff for outpatient services) code, or a new code must be established.
• Appendix 22 of the basis agreements between Statutory Health Insurance (SHI) and the SHI physicians may require national-level formal assessment to obtain a new EBM outpatient reimbursement code. Manufacturers would work with medical societies and professional physician organizations to get support for application of a new EBM code.
• Adoption will occur on a facility-by-facility basis.
• Manufacturers may work through the diagnostics industry association (VDGH, Association of Diagnostic Industry).
Market Access for POC Diagnostics: Inpatient Sector
• Hospital-level purchasing decisions are driven by physicians' needs and budgets. Stakeholders may include laboratory, unit and medical directors, and administration staff.
• Manufacturers should provide samples, a convincing data package, and an evidence dossier.
Italy
Market Access for POC Diagnostics: No Formal Route
• Historically, there has been no national-level evaluation of medical devices and diagnostics before market entry; however, the national HTA agency (AGENAS, Agency for Regional Health Services) is evaluating more medical devices and diagnostics.
• After obtaining a CE mark, market entry of medical devices and diagnostics is highly decentralized and is approached at the regional and/or local levels through negotiations (based on evidence of clinical usefulness, budget impact, and price).
Market Access for POC Diagnostics: Regional Level
• During clinical development, manufacturers should build stakeholder interest in the POC test. Conducting clinical trials in collaboration with KOLs can increase chances of adoption.
• After obtaining the CE mark, manufacturers should approach agenzias sanitaria regionale (ASRs, regional health agencies) to gain market access.
-Manufacturers should develop evidence dossiers that include key data supporting the value proposition (e.g., impact on patient adherence, resource use, and budget impact).
-Some regions (i.e., Emilia-Romagna and Veneto) have CRDM (regional medical device committees) associated with the ASRs that may evaluate the POC diagnostic.
Market Access for POC Diagnostics: Local Level
• Manufacturers should approach the ASLs (local health units), which administer the PSN (National Health Care Plan), to gain support and to initiate marketing and sales; manufacturers should provide an evidence dossier that incorporates clinical evidence, budget impact, and price, concentrating first on ASLs known to be early adopters of technology.
• Manufacturers should approach individual health care facilities and build support among physicians and facility directors/ administrators.
• In some outpatient hospital facilities, manufacturers may approach decision makers on hospital HTA committees (CPTOs), which evaluate drugs and medical devices and diagnostics for purchase.
Spain
Market Access for POC Diagnostics: No Formal Route
• National and/or regional HTA review is not necessary for hospital adoption of medical devices and diagnostics, although favorable national HTA review may lead to approval listing with the Spanish Medicine Agency (AEMPS).
• Hospitals can purchase medical devices and diagnostics from their own budgets, regardless of national HTA review (under DRG-based hospital systems).
Market Access for POC Diagnostics: Local Level
• Depending on device profile, acceptance decisions may be made at the hospital/clinic level. For innovative devices, the decision can be made at higher level.
• Manufacturers should approach decision makers at three to five hospital facilities. Per recommendation of hospital physicians, hospital committees evaluate drugs and medical devices and diagnostics for purchase.
• Hospital clinicians and manufacturers should negotiate with facility budget decision makers to have the POC diagnostic paid for by the health care facility budget, established by the regional authority. Initial adoption will continue using the same procedure at subsequent health care facilities.
Market Access for POC Diagnostics: Regional Level
• Once local-level use is established, manufacturers should approach the regional HTA agencies to conduct an evaluation of the POC diagnostic with support from leading academic facilities.
-Key elements are test performance, convenience, impact on the internal working processes (e.g., reduce workload, time, complexity), and price.
• If the regional HTA review is favorable, the region can require use of the POC diagnostic (still paid for within the health care facility budget).
• Health care facilities can choose to use the test and pay for it with their budget on a facility-by-facility basis. 
United Kingdom
Reimbursement of POC Diagnostics
• Three mechanisms are used by primary care trusts (PCTs) to pay for health care products and services:
-Payment by results: DRG system to fix prices for 1,000+ hospital procedures (e.g., diagnostic testing and some outpatient procedures).
-Block contracts: agreements between PCTs and health care providers to use and pay for a product or service.
-Global budgeting: purchasing products or services with the health care provider budget.
Market Access for POC Diagnostics: Start at the Local Level
• The UK is largely decentralized for medical devices and diagnostics, with no formal pathway to market access.
• Manufacturers should directly approach physicians and directors of health care teams and facilities and should use evidence communication materials (e.g., test performance, reliability, cost-effectiveness, price, budget impact, and anticipated cost savings).
Market Access for POC Diagnostics: Submission of Evidence to NICE
• Evidence dossiers for the National Institute for Care Excellence (NICE) require more rigorous data than those targeted to providers, strategic health authorities, mental health trusts, secondary care trusts, or PCTs.
• Manufacturer pricing is often public information upon assessment by NICE, providing a reduced latitude for negotiation at a provider-by-provider basis afterward.
Market Access for POC Diagnostics: Future Changes
• The UK is moving to a more centralized (albeit still regionalized) market for medical devices, with 151 local PCTs being replaced by regionalized GP commissioning consortia in 2014.
• Manufacturers should approach GP commissioning consortia directly rather than providers, mental health trusts, or secondary care trusts.
-GP consortia will require a NICE assessment to adopt POC diagnostics and solicit a NICE review if they are interested in adopting.
• Alternatively the manufacturer can initiate a NICE assessment at the national level.
CONCLUSIONS
• There are multiple access pathways for various theatres of care (e.g., outpatient office/clinic, inpatient, emergency), with varying requirements and value drivers.
• Adequate data to meet decision makers' needs is not well understood.
• Access for a POC test will be complex; regardless of pathway, decisions regarding reimbursement and adoption of new technology are diverse and dispersed across and within countries with varying levels of required evidence.
